Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ABBV-428 |
| Synonyms | |
| Therapy Description |
ABBV-428 is a bispecific antibody that binds TNFRSF5 (CD40) to stimulate immune cells and also binds a tumor associated antigen on cancer cells (PMID: 31462409). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ABBV-428 | ABBV428|ABBV 428 | CD40 Antibody 16 | ABBV-428 is a bispecific antibody that binds TNFRSF5 (CD40) to stimulate immune cells and also binds a tumor associated antigen on cancer cells (PMID: 31462409). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02955251 | Phase I | ABBV-428 + Nivolumab ABBV-428 | A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors | Completed | USA | FRA | AUS | 1 |